{ "FullStudy":{ "Rank":217615, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01519089", "OrgStudyIdInfo":{ "OrgStudyId":"A3921137" }, "Organization":{ "OrgFullName":"Pfizer", "OrgClass":"INDUSTRY" }, "BriefTitle":"A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis", "OfficialTitle":"A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis" }, "StatusModule":{ "StatusVerifiedDate":"August 2015", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"March 2012" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"January 2014", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"January 2014", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"December 22, 2011", "StudyFirstSubmitQCDate":"January 25, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 26, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"January 8, 2015", "ResultsFirstSubmitQCDate":"August 6, 2015", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"August 13, 2015", "ResultsFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"August 6, 2015", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"August 13, 2015", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Pfizer", "LeadSponsorClass":"INDUSTRY" } }, "OversightModule":{ "OversightHasDMC":"Yes" }, "DescriptionModule":{ "BriefSummary":"The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Psoriasis" ] }, "KeywordList":{ "Keyword":[ "chronic", "severe", "moderate", "treatment", "safety", "efficacy", "CP-690", "550", "Plaque psoriasis", "Psoriasis Vulgaris", "Psoriatic Arthritis", "tofacitinib", "Xeljanz" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 3" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Parallel Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"Quadruple", "DesignWhoMaskedList":{ "DesignWhoMasked":[ "Participant", "Care Provider", "Investigator", "Outcomes Assessor" ] } } }, "EnrollmentInfo":{ "EnrollmentCount":"95", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"CP-690,550 10 mg BID", "ArmGroupType":"Experimental", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: CP-690,550" ] } },{ "ArmGroupLabel":"CP690,550 5 mg BID", "ArmGroupType":"Experimental", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: CP-690, 550" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"CP-690,550", "InterventionDescription":"10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "CP-690,550 10 mg BID" ] } },{ "InterventionType":"Drug", "InterventionName":"CP-690, 550", "InterventionDescription":"5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "CP690,550 5 mg BID" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16", "PrimaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.", "PrimaryOutcomeTimeFrame":"Week 16" },{ "PrimaryOutcomeMeasure":"Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16", "PrimaryOutcomeDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).", "PrimaryOutcomeTimeFrame":"Week 16" },{ "PrimaryOutcomeMeasure":"Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16", "PrimaryOutcomeDescription":"ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "PrimaryOutcomeTimeFrame":"Week 16" },{ "PrimaryOutcomeMeasure":"Number of Participants With Adjudicated Cardiovacular Events", "PrimaryOutcomeDescription":"Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.", "PrimaryOutcomeTimeFrame":"Baseline to Follow-up" },{ "PrimaryOutcomeMeasure":"Number of Participants With Malignancy Events _Week 0 Through Follow-up", "PrimaryOutcomeDescription":"For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.", "PrimaryOutcomeTimeFrame":"Baseline to Follow-up" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'", "SecondaryOutcomeDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "SecondaryOutcomeTimeFrame":"Week 16" },{ "SecondaryOutcomeMeasure":"Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and \"percent of BSA\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "SecondaryOutcomeTimeFrame":"Week 16" },{ "SecondaryOutcomeMeasure":"Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and \"percent of BSA\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "SecondaryOutcomeTimeFrame":"Week 16" },{ "SecondaryOutcomeMeasure":"Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and \"percent of BSA\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "SecondaryOutcomeTimeFrame":"Week 16" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in Psoriasis Area and Severity Index (PASI) Score", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'", "SecondaryOutcomeDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category", "SecondaryOutcomeDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16", "SecondaryOutcomeDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.", "SecondaryOutcomeTimeFrame":"Week 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'", "SecondaryOutcomeDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.", "SecondaryOutcomeTimeFrame":"Week 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score", "SecondaryOutcomeDescription":"The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.", "SecondaryOutcomeTimeFrame":"Week 8, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Number of Affected Nails", "SecondaryOutcomeDescription":"Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.", "SecondaryOutcomeTimeFrame":"Baseline, Week 8, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Itch Severity Item (ISI) Score", "SecondaryOutcomeDescription":"ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate \"your worst itching due to psoriasis over the past 24 hours\" on a numeric rating scale anchored by the terms \"No itching\" (0) and \"Worst possible itching\" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.", "SecondaryOutcomeTimeFrame":"Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Dermatology Life Quality Index (DLQI) Score", "SecondaryOutcomeDescription":"The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.", "SecondaryOutcomeTimeFrame":"Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score", "SecondaryOutcomeDescription":"36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).", "SecondaryOutcomeTimeFrame":"Week (W) 16, 28, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score", "SecondaryOutcomeDescription":"36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).", "SecondaryOutcomeTimeFrame":"Week 16, 28, 52" },{ "SecondaryOutcomeMeasure":"Work Limitation Questionnaire (WLQ)", "SecondaryOutcomeDescription":"WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).", "SecondaryOutcomeTimeFrame":"Baseline (BL), Week (W) 4, 16, 28, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category", "SecondaryOutcomeDescription":"The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).", "SecondaryOutcomeTimeFrame":"Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Joint Pain Assessment (JPA)", "SecondaryOutcomeDescription":"The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to \"select the number that best describes any joint pain that participant may have experienced over the past 24 hours\" with response options ranging from \"0-no joint pain\" to \"10-worst possible joint pain.\"", "SecondaryOutcomeTimeFrame":"Baseline, Week 4, 16, 28, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response", "SecondaryOutcomeDescription":"ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response", "SecondaryOutcomeDescription":"ACR50 response: greater than or equal to (>=) 50 percent (%) improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response", "SecondaryOutcomeDescription":"ACR70 response: greater than or equal to (>=) 70 percent (%) improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count", "SecondaryOutcomeDescription":"Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count", "SecondaryOutcomeDescription":"Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain", "SecondaryOutcomeDescription":"Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis", "SecondaryOutcomeDescription":"Subjects answered the following question, \"Considering the possible effects of the arthritis, how are you feeling today?\" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis", "SecondaryOutcomeDescription":"The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)", "SecondaryOutcomeDescription":"The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" },{ "SecondaryOutcomeMeasure":"Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)", "SecondaryOutcomeDescription":"HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.", "SecondaryOutcomeTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nAre 20 years or older and considered to be candidates for systemic or phototherapy.\n\n[Moderate to Severe Plaque Psoriasis]\n\nDiagnosed for at least 12 months.\nHave Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis covering at least 10% of body surface area (BSA).\n\n[Psoriatic Arthritis]\n\nDiagnosed for at least 6 months.\nMeet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at screening;\nHave active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and active plaque psoriasis with at least 2 cm in diameter.\n\nExclusion Criteria:\n\nNon-plaque or drug induced forms of psoriasis\nCannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic arthritis or cannot discontinue phototherapy (PUVA or UVB)\nany uncontrolled significant medical condition", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"20 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Pfizer CT.gov Call Center", "OverallOfficialAffiliation":"Pfizer", "OverallOfficialRole":"Study Director" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"JR Sapporo hospital", "LocationCity":"Sapporo", "LocationState":"Hokkaido", "LocationZip":"060-0033", "LocationCountry":"Japan" },{ "LocationFacility":"Kobe University Hospital", "LocationCity":"Chuo-ku, Kobe", "LocationState":"Hyogo", "LocationZip":"650-0017", "LocationCountry":"Japan" },{ "LocationFacility":"Kanazawa Medical University Hospital", "LocationCity":"Kahoku-gun", "LocationState":"Ishikawa", "LocationZip":"920-0293", "LocationCountry":"Japan" },{ "LocationFacility":"National Hospital Organization Sagamihara National Hospital", "LocationCity":"Sagamihara", "LocationState":"Kanagawa", "LocationZip":"252-0392", "LocationCountry":"Japan" },{ "LocationFacility":"University of Miyazaki Hospital", "LocationCity":"Miyazaki-shi", "LocationState":"Miyazaki", "LocationZip":"889-1692", "LocationCountry":"Japan" },{ "LocationFacility":"Jichi Medical University Hospital", "LocationCity":"Shimotsuke", "LocationState":"Tochigi", "LocationZip":"324-0498", "LocationCountry":"Japan" },{ "LocationFacility":"Tokyo Teishin Hospital", "LocationCity":"Chiyoda-ku", "LocationState":"Tokyo", "LocationZip":"102-8798", "LocationCountry":"Japan" },{ "LocationFacility":"Tokyo medical university Hachioji medical center", "LocationCity":"Hachioji", "LocationState":"Tokyo", "LocationZip":"193-0998", "LocationCountry":"Japan" },{ "LocationFacility":"Kanto Medical Center NTT East Corporation", "LocationCity":"Shinagawa-ku", "LocationState":"Tokyo", "LocationZip":"141-8625", "LocationCountry":"Japan" },{ "LocationFacility":"Tokyo Medical University Hospital", "LocationCity":"Shinjyuku-ku", "LocationState":"Tokyo", "LocationZip":"160-0023", "LocationCountry":"Japan" },{ "LocationFacility":"Tonami General Hospital", "LocationCity":"Tonami", "LocationState":"Toyama", "LocationZip":"939-1395", "LocationCountry":"Japan" },{ "LocationFacility":"Yamanashi Prefectural Central Hospital", "LocationCity":"Kofu", "LocationState":"Yamanashi", "LocationZip":"400-8506", "LocationCountry":"Japan" },{ "LocationFacility":"Fukuoka University Hospital", "LocationCity":"Fukuoka", "LocationZip":"814-0180", "LocationCountry":"Japan" },{ "LocationFacility":"Fukushima Medical University Hospital", "LocationCity":"Fukushima", "LocationZip":"960-1295", "LocationCountry":"Japan" },{ "LocationFacility":"Nissay Hospital", "LocationCity":"Osaka", "LocationZip":"550-0012", "LocationCountry":"Japan" },{ "LocationFacility":"Jikei University Hospital", "LocationCity":"Tokyo", "LocationZip":"105-8471", "LocationCountry":"Japan" } ] } }, "ReferencesModule":{ "SeeAlsoLinkList":{ "SeeAlsoLink":[ { "SeeAlsoLinkLabel":"To obtain contact information for a study center near you, click here.", "SeeAlsoLinkURL":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921137&StudyName=A%20Long%20Term%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%20And%20Efficacy%20Of%20CP-690%2C550%20In%20Patients%20With%20Moderate%20To%20Severe%20Plaque%20Psori" } ] } } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"CP-690,550 5 mg BID", "FlowGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "FlowGroupId":"FG001", "FlowGroupTitle":"CP-690,550 10 mg BID", "FlowGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"Overall Study", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"47" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"48" } ] } },{ "FlowMilestoneType":"Received Treatment", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"47" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"47" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"40" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"33" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"7" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"15" } ] } } ] }, "FlowDropWithdrawList":{ "FlowDropWithdraw":[ { "FlowDropWithdrawType":"Adverse Event", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"4" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"4" } ] } },{ "FlowDropWithdrawType":"Lack of Efficacy", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"2" } ] } },{ "FlowDropWithdrawType":"Lost to Follow-up", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"1" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"0" } ] } },{ "FlowDropWithdrawType":"Withdrawal by Subject", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"2" } ] } },{ "FlowDropWithdrawType":"Other", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"2" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"6" } ] } },{ "FlowDropWithdrawType":"Not received study drug", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"1" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"CP-690,550 5 mg BID", "BaselineGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "BaselineGroupId":"BG001", "BaselineGroupTitle":"CP-690,550 10 mg BID", "BaselineGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "BaselineGroupId":"BG002", "BaselineGroupTitle":"Total", "BaselineGroupDescription":"Total of all reporting groups" } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"47" },{ "BaselineDenomCountGroupId":"BG001", "BaselineDenomCountValue":"47" },{ "BaselineDenomCountGroupId":"BG002", "BaselineDenomCountValue":"94" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Standard Deviation", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"50.9", "BaselineMeasurementSpread":"11.8" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"46.4", "BaselineMeasurementSpread":"10.8" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"48.7", "BaselineMeasurementSpread":"11.5" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"8" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"8" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"16" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"39" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"39" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"78" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"62.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"72.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"67.8" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16", "OutcomeMeasureDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"67.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"68.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"67.8" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16", "OutcomeMeasureDescription":"ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"100" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Number of Participants With Adjudicated Cardiovacular Events", "OutcomeMeasureDescription":"Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.", "OutcomeMeasurePopulationDescription":"Participants treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Baseline to Follow-up", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"47" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"47" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"94" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Number of Participants With Malignancy Events _Week 0 Through Follow-up", "OutcomeMeasureDescription":"For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.", "OutcomeMeasurePopulationDescription":"Participants treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Baseline to Follow-up", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"47" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"47" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"94" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Number of participants with any malignancy events", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Malignancy excluding non-melanoma skin cancer", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Lymphoma/Lymphoproliferative disorders (LPD)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Melanoma", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Non-melanoma skin cancer", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"22.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"14.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"41.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"54.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"48.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"60.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"70.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"65.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"67.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"63.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"65.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"69.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"65.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"67.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"69.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"63.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"66.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"62.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"63.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"63.2" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"9.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"22.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"16.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"34.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"56.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"46.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"60.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"81.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"71.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"81.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"84.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"82.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"76.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"79.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"78.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"79.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"77.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"90.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"72.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"81.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"88.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"79.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"90.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"68.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"79.3" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"13.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"9.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"16.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"29.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"23.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"37.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"45.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"41.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"37.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"54.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"46.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"58.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"56.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"57.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"55.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"45.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"50.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"58.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"47.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"52.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"51.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"47.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"49.4" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'", "OutcomeMeasureDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"Week", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"8.0", "OutcomeMeasurementLowerLimit":"8.0", "OutcomeMeasurementUpperLimit":"12.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.0", "OutcomeMeasurementLowerLimit":"4.0", "OutcomeMeasurementUpperLimit":"12.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.0", "OutcomeMeasurementLowerLimit":"NA", "OutcomeMeasurementUpperLimit":"NA", "OutcomeMeasurementComment":"The 95 percent confidence interval could not be constructed." } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and \"percent of BSA\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"Week", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"12.0", "OutcomeMeasurementLowerLimit":"8.0", "OutcomeMeasurementUpperLimit":"16.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.0", "OutcomeMeasurementLowerLimit":"8.0", "OutcomeMeasurementUpperLimit":"12.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"12.0", "OutcomeMeasurementLowerLimit":"8.0", "OutcomeMeasurementUpperLimit":"12.0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and \"percent of BSA\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"Week", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"8.0", "OutcomeMeasurementLowerLimit":"4.0", "OutcomeMeasurementUpperLimit":"12.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.0", "OutcomeMeasurementLowerLimit":"4.0", "OutcomeMeasurementUpperLimit":"8.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.0", "OutcomeMeasurementLowerLimit":"4.0", "OutcomeMeasurementUpperLimit":"8.0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and \"percent of BSA\" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"Week", "OutcomeMeasureTimeFrame":"Week 16", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"NA", "OutcomeMeasurementLowerLimit":"12.0", "OutcomeMeasurementUpperLimit":"NA", "OutcomeMeasurementComment":"The median time could not be computed because fewer than half of the subjects achieved a PASI90 response." },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"12.0", "OutcomeMeasurementLowerLimit":"12.0", "OutcomeMeasurementUpperLimit":"16.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"16.0", "OutcomeMeasurementLowerLimit":"12.0", "OutcomeMeasurementUpperLimit":"NA", "OutcomeMeasurementComment":"The 95 percent upper limit could not be computed due to the limited analysis duration up to Week 16." } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 8 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 12 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 20 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in Psoriasis Area and Severity Index (PASI) Score", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-5.18", "OutcomeMeasurementSpread":"5.898" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-7.36", "OutcomeMeasurementSpread":"6.428" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-6.28", "OutcomeMeasurementSpread":"6.232" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-10.40", "OutcomeMeasurementSpread":"7.518" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-13.16", "OutcomeMeasurementSpread":"8.739" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-11.79", "OutcomeMeasurementSpread":"8.229" } ] } } ] } },{ "OutcomeClassTitle":"Week 8 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-15.95", "OutcomeMeasurementSpread":"8.392" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-19.90", "OutcomeMeasurementSpread":"10.741" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-17.88", "OutcomeMeasurementSpread":"9.756" } ] } } ] } },{ "OutcomeClassTitle":"Week 12 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-18.91", "OutcomeMeasurementSpread":"8.918" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-21.68", "OutcomeMeasurementSpread":"11.598" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-20.26", "OutcomeMeasurementSpread":"10.344" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-19.53", "OutcomeMeasurementSpread":"9.094" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-22.06", "OutcomeMeasurementSpread":"12.606" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-20.75", "OutcomeMeasurementSpread":"10.935" } ] } } ] } },{ "OutcomeClassTitle":"Week 20 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-20.95", "OutcomeMeasurementSpread":"9.239" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-22.18", "OutcomeMeasurementSpread":"12.045" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-21.53", "OutcomeMeasurementSpread":"10.617" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-21.77", "OutcomeMeasurementSpread":"10.196" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-21.46", "OutcomeMeasurementSpread":"10.503" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-21.62", "OutcomeMeasurementSpread":"10.280" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-22.20", "OutcomeMeasurementSpread":"10.181" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-21.18", "OutcomeMeasurementSpread":"10.229" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-21.71", "OutcomeMeasurementSpread":"10.151" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-21.96", "OutcomeMeasurementSpread":"9.621" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-22.11", "OutcomeMeasurementSpread":"10.598" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-22.03", "OutcomeMeasurementSpread":"10.000" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2: Erythema (Head/Neck)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.5", "OutcomeMeasurementSpread":"0.83" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.9", "OutcomeMeasurementSpread":"0.82" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.84" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Erythema (Upper Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.5", "OutcomeMeasurementSpread":"0.67" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.72" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.70" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Erythema (Trunk)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.67" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.69" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.69" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Erythema (Lower Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.69" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.71" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.70" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Induration (Head/Neck)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.4", "OutcomeMeasurementSpread":"0.70" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.89" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.82" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Induration (Upper Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.5", "OutcomeMeasurementSpread":"0.63" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.75" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.69" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Induration (Trunk)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.5", "OutcomeMeasurementSpread":"0.63" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.59" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.62" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Induration (Lower Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.5", "OutcomeMeasurementSpread":"0.67" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.71" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.69" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Scaling (Head/Neck)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.4", "OutcomeMeasurementSpread":"0.66" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.9", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.83" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Scaling (Upper Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.4", "OutcomeMeasurementSpread":"0.59" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.74" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.69" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Scaling (Trunk)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.3", "OutcomeMeasurementSpread":"0.57" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.76" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.71" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Scaling (Lower Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.4", "OutcomeMeasurementSpread":"0.70" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.73" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.6", "OutcomeMeasurementSpread":"0.73" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Erythema (Head/Neck)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"1.02" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"1.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Erythema (Upper Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.81" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.87" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Erythema (Trunk)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"0.64" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.79" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.72" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Erythema (Lower Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"0.79" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"0.85" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Induration (Head/Neck)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.7", "OutcomeMeasurementSpread":"0.89" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"1.09" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"1.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Induration (Upper Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.86" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"0.85" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"0.85" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Induration (Trunk)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.9", "OutcomeMeasurementSpread":"0.80" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.82" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.83" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Induration (Lower Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"0.90" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.94" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Scaling (Head/Neck)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.86" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"0.95" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Scaling (Upper Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.9", "OutcomeMeasurementSpread":"0.70" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.2", "OutcomeMeasurementSpread":"0.86" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.0", "OutcomeMeasurementSpread":"0.79" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Scaling (Trunk)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.9", "OutcomeMeasurementSpread":"0.71" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.95" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.87" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Scaling (Lower Limbs)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.8", "OutcomeMeasurementSpread":"0.72" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.1", "OutcomeMeasurementSpread":"0.89" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Erythema (Head/Neck) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"1.13" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.08" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Erythema (Upper Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.95" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Erythema (Trunk) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.92" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Erythema (Lower Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.91" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Induration (Head/Neck) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Induration (Upper Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.89" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.91" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Induration (Trunk) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.00" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Induration (Lower Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.94" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Scaling (Head/Neck) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.90" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"0.96" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Scaling (Upper Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.80" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.86" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.84" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Scaling (Trunk) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"0.82" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.00" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.93" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Scaling (Lower Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.3", "OutcomeMeasurementSpread":"0.82" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.88" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.88" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Erythema (Head/Neck) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.10" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Erythema (Upper Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.13" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.05" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Erythema (Trunk) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.08" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"0.95" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Erythema (Lower Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.92" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.92" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Induration (Head/Neck) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.12" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Induration (Upper Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.96" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Induration (Trunk) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.00" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.00" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Induration (Lower Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.06" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.98" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Scaling (Head/Neck) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.92" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.02" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.96" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Scaling (Upper Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"0.91" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.95" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.94" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Scaling (Trunk) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.00" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.03" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Scaling (Lower Limbs) (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.85" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.00" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.95" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Erythema (Head/Neck) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.14" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.10" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Erythema (Upper Limbs) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.13" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.12" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.12" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Erythema (Trunk) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.10" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.08" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Erythema (Lower Limbs) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"0.99" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Induration (Head/Neck) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.17" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.06" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Induration (Upper Limbs) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.98" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Induration (Trunk) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Induration (Lower Limbs) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"0.95" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.08" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Scaling (Head/Neck) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.95" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.08" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Scaling (Upper Limbs) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.99" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Scaling (Trunk) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.09" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Scaling (Lower Limbs) (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.06" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.00" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Erythema (Head/Neck) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.15" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.07" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Erythema (Upper Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.97" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.26" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.11" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Erythema (Trunk) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"1.04" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.04" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Erythema (Lower Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.04" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.09" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.05" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Induration (Head/Neck) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.00" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.12" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.06" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Induration (Upper Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.97" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.14" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.05" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Induration (Trunk) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Induration (Lower Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.95" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.06" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.00" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Scaling (Head/Neck) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.99" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Scaling (Upper Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.14" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Scaling (Trunk) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.99" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Scaling (Lower Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.92" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.16" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Erythema (Head/Neck) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.11" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.81" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.98" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Erythema (Upper Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.09" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.08" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Erythema (Trunk) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.13" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.06" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Erythema (Lower Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.3", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.03" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Induration (Head/Neck) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.97" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.98" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Induration (Upper Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.12" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.12" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Induration (Trunk) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.12" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.16" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.14" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Induration (Lower Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.14" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.09" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Scaling (Head/Neck) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"1.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Scaling (Upper Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.02" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.03" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Scaling (Trunk) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.99" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.11" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.05" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Scaling (Lower Limbs) (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.09" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.02" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.05" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Erythema (Head/Neck) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.10" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.90" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Erythema (Upper Limbs) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.06" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.06" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Erythema (Trunk) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.04" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.87" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.95" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Erythema (Lower Limbs) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.4", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"1.05" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Induration (Head/Neck) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.05" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.08" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.07" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Induration (Upper Limbs) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.18" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.09" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Induration (Trunk) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.26" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.11" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Induration (Lower Limbs) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"1.14" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.10" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Scaling (Head/Neck) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.97" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.4", "OutcomeMeasurementSpread":"1.00" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.99" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Scaling (Upper Limbs) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.10" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Scaling (Trunk) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.98" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Scaling (Lower Limbs) (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.11" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.06" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.08" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Erythema (Head/Neck) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.17" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.24" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.20" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Erythema (Upper Limbs) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.15" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"0.90" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.04" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Erythema (Trunk) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.93" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.97" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Erythema (Lower Limbs) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.11" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.94" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.03" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Induration (Head/Neck) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.06" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.5", "OutcomeMeasurementSpread":"1.22" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.13" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Induration (Upper Limbs) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.21" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"0.97" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.10" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Induration (Trunk) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.39" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.24" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Induration (Lower Limbs) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.29" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.2", "OutcomeMeasurementSpread":"0.97" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.1", "OutcomeMeasurementSpread":"1.15" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Scaling (Head/Neck) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.08" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Scaling (Upper Limbs) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"1.02" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"0.98" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.01" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Scaling (Trunk) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.6", "OutcomeMeasurementSpread":"0.96" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.9", "OutcomeMeasurementSpread":"1.01" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"0.98" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Scaling (Lower Limbs) (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.7", "OutcomeMeasurementSpread":"1.15" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-2.0", "OutcomeMeasurementSpread":"1.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'", "OutcomeMeasureDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"15.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"11.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"30.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"38.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"34.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"58.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"61.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"59.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"72.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"73.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"72.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"59.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"65.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"67.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"54.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"60.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"67.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"54.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"60.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"58.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"56.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"57.5" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category", "OutcomeMeasureDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2: Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Almost Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"15.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"11.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Mild", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"39.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"43.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"41.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Moderate", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"46.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"34.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"40.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Severe", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"11.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Almost Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"30.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"27.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"28.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Mild", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"44.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"40.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"42.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Moderate", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"18.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"20.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"19.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Severe", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"26.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"16.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Almost Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"51.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"39.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"45.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Mild (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"27.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"24.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Moderate (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"14.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"9.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"11.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Severe (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"14.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"36.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"25.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Almost Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"58.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"43.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"51.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Mild (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"20.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"9.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"15.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Moderate (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"9.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Severe (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Clear (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"27.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"40.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"33.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Almost Clear (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"39.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"35.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"37.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Mild (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"25.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"17.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"21.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Moderate (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Severe (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"27.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"38.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"32.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Almost Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"44.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"28.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"36.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Mild (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"18.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"25.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"22.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Moderate (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"9.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Severe(n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"37.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"33.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"35.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Almost Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"30.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"28.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"29.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Mild (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"27.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"30.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"29.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Moderate (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Severe (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Clear (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"43.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"34.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"39.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Almost Clear (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"26.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"28.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"27.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Mild (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"24.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"28.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Moderate (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Severe (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Clear (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"41.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"43.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"42.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Almost Clear (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"23.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"34.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"28.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Mild (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"30.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"18.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"25.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Moderate (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Severe (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16", "OutcomeMeasureDescription":"The PASI quantifies the severity of a participant's psoriasis based on both, \"lesion severity\" and the \"percent of body surface area (BSA)\" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"28" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"35" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"63" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"96.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"92.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"78.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"84.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"81.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"71.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"76.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"70.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"62.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"66.1" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'", "OutcomeMeasureDescription":"The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"31" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"61" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"83.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"93.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"73.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"82.8" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"66.7" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"74.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"65.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"60.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"62.7" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score", "OutcomeMeasureDescription":"The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 8, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"32" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"62" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 8 (n=32, 28, 60)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-3.3", "OutcomeMeasurementSpread":"9.63" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"7.72" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.6", "OutcomeMeasurementSpread":"8.75" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=32, 28, 60)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-11.2", "OutcomeMeasurementSpread":"15.27" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-9.4", "OutcomeMeasurementSpread":"12.66" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-10.4", "OutcomeMeasurementSpread":"14.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 20 (n=32, 27, 59)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-15.0", "OutcomeMeasurementSpread":"15.29" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-14.1", "OutcomeMeasurementSpread":"13.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-14.6", "OutcomeMeasurementSpread":"14.18" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=32, 27, 59)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-21.1", "OutcomeMeasurementSpread":"15.83" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-16.4", "OutcomeMeasurementSpread":"15.27" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-18.9", "OutcomeMeasurementSpread":"15.62" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=31, 26, 57)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-22.2", "OutcomeMeasurementSpread":"16.18" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-16.2", "OutcomeMeasurementSpread":"14.13" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-19.5", "OutcomeMeasurementSpread":"15.45" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=30, 22, 52)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-20.6", "OutcomeMeasurementSpread":"15.16" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-16.2", "OutcomeMeasurementSpread":"15.62" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-18.7", "OutcomeMeasurementSpread":"15.36" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number of Affected Nails", "OutcomeMeasureDescription":"Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"nails", "OutcomeMeasureTimeFrame":"Baseline, Week 8, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"32" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"62" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Baseline", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.94", "OutcomeMeasurementSpread":"2.82" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.13", "OutcomeMeasurementSpread":"3.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.55", "OutcomeMeasurementSpread":"2.95" } ] } } ] } },{ "OutcomeClassTitle":"Week 8 (n=32, 28, 60)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.66", "OutcomeMeasurementSpread":"3.17" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.11", "OutcomeMeasurementSpread":"3.02" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.40", "OutcomeMeasurementSpread":"3.09" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=32, 28, 60)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.91", "OutcomeMeasurementSpread":"3.43" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.75", "OutcomeMeasurementSpread":"3.56" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.37", "OutcomeMeasurementSpread":"3.51" } ] } } ] } },{ "OutcomeClassTitle":"Week 20 (n=32, 27, 59)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.16", "OutcomeMeasurementSpread":"3.60" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.59", "OutcomeMeasurementSpread":"4.02" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.44", "OutcomeMeasurementSpread":"3.85" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=32, 27, 59)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.53", "OutcomeMeasurementSpread":"3.87" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.59", "OutcomeMeasurementSpread":"3.96" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.10", "OutcomeMeasurementSpread":"3.91" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=31, 26, 57)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3.32", "OutcomeMeasurementSpread":"3.94" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.77", "OutcomeMeasurementSpread":"3.81" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.53", "OutcomeMeasurementSpread":"3.85" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=30, 22, 52)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3.73", "OutcomeMeasurementSpread":"4.25" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.50", "OutcomeMeasurementSpread":"3.07" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.21", "OutcomeMeasurementSpread":"3.81" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Itch Severity Item (ISI) Score", "OutcomeMeasureDescription":"ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate \"your worst itching due to psoriasis over the past 24 hours\" on a numeric rating scale anchored by the terms \"No itching\" (0) and \"Worst possible itching\" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Baseline", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.16", "OutcomeMeasurementSpread":"2.669" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.32", "OutcomeMeasurementSpread":"2.967" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.74", "OutcomeMeasurementSpread":"2.839" } ] } } ] } },{ "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.19", "OutcomeMeasurementSpread":"2.797" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.30", "OutcomeMeasurementSpread":"2.530" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.23", "OutcomeMeasurementSpread":"2.815" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3.65", "OutcomeMeasurementSpread":"2.379" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.27", "OutcomeMeasurementSpread":"2.472" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.95", "OutcomeMeasurementSpread":"2.510" } ] } } ] } },{ "OutcomeClassTitle":"Week 8 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.26", "OutcomeMeasurementSpread":"2.381" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.22", "OutcomeMeasurementSpread":"1.739" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.75", "OutcomeMeasurementSpread":"2.145" } ] } } ] } },{ "OutcomeClassTitle":"Week 12 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.77", "OutcomeMeasurementSpread":"2.379" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.20", "OutcomeMeasurementSpread":"1.833" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.49", "OutcomeMeasurementSpread":"2.137" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.67", "OutcomeMeasurementSpread":"2.378" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.90", "OutcomeMeasurementSpread":"1.257" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.30", "OutcomeMeasurementSpread":"1.949" } ] } } ] } },{ "OutcomeClassTitle":"Week 20 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.95", "OutcomeMeasurementSpread":"1.618" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.28", "OutcomeMeasurementSpread":"1.589" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.11", "OutcomeMeasurementSpread":"1.603" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.12", "OutcomeMeasurementSpread":"1.651" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.62", "OutcomeMeasurementSpread":"2.196" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.35", "OutcomeMeasurementSpread":"1.933" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.90", "OutcomeMeasurementSpread":"1.814" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.13", "OutcomeMeasurementSpread":"1.848" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.01", "OutcomeMeasurementSpread":"1.822" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.15", "OutcomeMeasurementSpread":"2.084" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.91", "OutcomeMeasurementSpread":"1.329" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.04", "OutcomeMeasurementSpread":"1.776" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Dermatology Life Quality Index (DLQI) Score", "OutcomeMeasureDescription":"The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Baseline", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"11.3", "OutcomeMeasurementSpread":"6.25" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.6", "OutcomeMeasurementSpread":"5.91" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"9.9", "OutcomeMeasurementSpread":"6.19" } ] } } ] } },{ "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.8", "OutcomeMeasurementSpread":"5.20" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.8", "OutcomeMeasurementSpread":"5.32" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.8", "OutcomeMeasurementSpread":"5.32" } ] } } ] } },{ "OutcomeClassTitle":"Week 4 (n=43, 43, 86)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.9", "OutcomeMeasurementSpread":"5.07" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.2", "OutcomeMeasurementSpread":"4.63" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.1", "OutcomeMeasurementSpread":"4.90" } ] } } ] } },{ "OutcomeClassTitle":"Week 8 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.0", "OutcomeMeasurementSpread":"3.95" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.8", "OutcomeMeasurementSpread":"3.30" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.4", "OutcomeMeasurementSpread":"3.67" } ] } } ] } },{ "OutcomeClassTitle":"Week 12 (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.6", "OutcomeMeasurementSpread":"2.86" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.8", "OutcomeMeasurementSpread":"2.68" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.2", "OutcomeMeasurementSpread":"2.79" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.2", "OutcomeMeasurementSpread":"3.04" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.9", "OutcomeMeasurementSpread":"2.73" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.1", "OutcomeMeasurementSpread":"2.88" } ] } } ] } },{ "OutcomeClassTitle":"Week 20 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.9", "OutcomeMeasurementSpread":"3.13" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.8", "OutcomeMeasurementSpread":"2.54" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.9", "OutcomeMeasurementSpread":"2.84" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.7", "OutcomeMeasurementSpread":"2.66" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.9", "OutcomeMeasurementSpread":"3.68" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.3", "OutcomeMeasurementSpread":"3.23" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.8", "OutcomeMeasurementSpread":"2.81" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.3", "OutcomeMeasurementSpread":"4.11" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.0", "OutcomeMeasurementSpread":"3.48" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.6", "OutcomeMeasurementSpread":"2.42" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.2", "OutcomeMeasurementSpread":"4.00" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.9", "OutcomeMeasurementSpread":"3.22" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score", "OutcomeMeasureDescription":"36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week (W) 16, 28, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"W16: Physical Functioning Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.951", "OutcomeMeasurementSpread":"5.1880" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.809", "OutcomeMeasurementSpread":"9.1822" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.329", "OutcomeMeasurementSpread":"7.4800" } ] } } ] } },{ "OutcomeClassTitle":"W16: Role-Physical Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.160", "OutcomeMeasurementSpread":"9.3615" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.130", "OutcomeMeasurementSpread":"11.1600" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.664", "OutcomeMeasurementSpread":"10.2172" } ] } } ] } },{ "OutcomeClassTitle":"W16: Bodily Pain Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"11.808", "OutcomeMeasurementSpread":"13.8431" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10.663", "OutcomeMeasurementSpread":"12.2936" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"11.256", "OutcomeMeasurementSpread":"13.0524" } ] } } ] } },{ "OutcomeClassTitle":"W16: General Health Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.392", "OutcomeMeasurementSpread":"7.0933" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.333", "OutcomeMeasurementSpread":"7.0145" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.328", "OutcomeMeasurementSpread":"7.0799" } ] } } ] } },{ "OutcomeClassTitle":"W16: Vitality Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.664", "OutcomeMeasurementSpread":"9.5406" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.517", "OutcomeMeasurementSpread":"11.4421" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.112", "OutcomeMeasurementSpread":"10.4509" } ] } } ] } },{ "OutcomeClassTitle":"W16: Social Function Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.629", "OutcomeMeasurementSpread":"9.9734" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.932", "OutcomeMeasurementSpread":"8.8645" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.775", "OutcomeMeasurementSpread":"9.3992" } ] } } ] } },{ "OutcomeClassTitle":"W16: Role-Emotional Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.219", "OutcomeMeasurementSpread":"11.5898" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.584", "OutcomeMeasurementSpread":"11.5654" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.431", "OutcomeMeasurementSpread":"11.5365" } ] } } ] } },{ "OutcomeClassTitle":"W16: Mental Health Domain (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.928", "OutcomeMeasurementSpread":"12.8757" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.125", "OutcomeMeasurementSpread":"13.3613" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.541", "OutcomeMeasurementSpread":"13.0378" } ] } } ] } },{ "OutcomeClassTitle":"W28: Physical Functioning Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.571", "OutcomeMeasurementSpread":"6.3446" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.303", "OutcomeMeasurementSpread":"10.3695" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.870", "OutcomeMeasurementSpread":"8.5558" } ] } } ] } },{ "OutcomeClassTitle":"W28: Role-Physical Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.882", "OutcomeMeasurementSpread":"10.6375" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.017", "OutcomeMeasurementSpread":"11.4671" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.471", "OutcomeMeasurementSpread":"10.9795" } ] } } ] } },{ "OutcomeClassTitle":"W28: Bodily Pain Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"10.113", "OutcomeMeasurementSpread":"15.9485" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.394", "OutcomeMeasurementSpread":"12.5405" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"9.295", "OutcomeMeasurementSpread":"14.3670" } ] } } ] } },{ "OutcomeClassTitle":"W28: General Health Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.644", "OutcomeMeasurementSpread":"5.9230" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.517", "OutcomeMeasurementSpread":"7.1375" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.059", "OutcomeMeasurementSpread":"6.5025" } ] } } ] } },{ "OutcomeClassTitle":"W28: Vitality Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.038", "OutcomeMeasurementSpread":"10.0116" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.608", "OutcomeMeasurementSpread":"10.0742" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.833", "OutcomeMeasurementSpread":"9.9815" } ] } } ] } },{ "OutcomeClassTitle":"W28: Social Function Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.628", "OutcomeMeasurementSpread":"11.3068" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6.205", "OutcomeMeasurementSpread":"10.4347" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.427", "OutcomeMeasurementSpread":"10.8358" } ] } } ] } },{ "OutcomeClassTitle":"W28: Role-Emotional Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.395", "OutcomeMeasurementSpread":"11.8846" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6.310", "OutcomeMeasurementSpread":"12.9504" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.879", "OutcomeMeasurementSpread":"12.3375" } ] } } ] } },{ "OutcomeClassTitle":"W28: Mental Health Domain (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.701", "OutcomeMeasurementSpread":"12.4375" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.328", "OutcomeMeasurementSpread":"12.8129" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.048", "OutcomeMeasurementSpread":"12.5580" } ] } } ] } },{ "OutcomeClassTitle":"W52: Physical Functioning Domain (n=39,32,71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.151", "OutcomeMeasurementSpread":"5.6134" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.773", "OutcomeMeasurementSpread":"7.3533" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.882", "OutcomeMeasurementSpread":"6.4585" } ] } } ] } },{ "OutcomeClassTitle":"W52: Role-Physical Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.669", "OutcomeMeasurementSpread":"10.0520" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.623", "OutcomeMeasurementSpread":"9.7340" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.747", "OutcomeMeasurementSpread":"9.8926" } ] } } ] } },{ "OutcomeClassTitle":"W52: Bodily Pain Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"12.335", "OutcomeMeasurementSpread":"12.1413" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10.673", "OutcomeMeasurementSpread":"9.7128" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"11.586", "OutcomeMeasurementSpread":"11.0678" } ] } } ] } },{ "OutcomeClassTitle":"W52: General Health Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.758", "OutcomeMeasurementSpread":"6.0866" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.888", "OutcomeMeasurementSpread":"6.8235" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3.718", "OutcomeMeasurementSpread":"6.4707" } ] } } ] } },{ "OutcomeClassTitle":"W52: Vitality Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.068", "OutcomeMeasurementSpread":"10.5612" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.052", "OutcomeMeasurementSpread":"8.5160" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.511", "OutcomeMeasurementSpread":"9.6390" } ] } } ] } },{ "OutcomeClassTitle":"W52: Social Function Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"8.411", "OutcomeMeasurementSpread":"9.4598" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.402", "OutcomeMeasurementSpread":"9.2577" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.407", "OutcomeMeasurementSpread":"9.3024" } ] } } ] } },{ "OutcomeClassTitle":"W52: Role-Emotional Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"8.445", "OutcomeMeasurementSpread":"11.0018" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.915", "OutcomeMeasurementSpread":"10.3091" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.305", "OutcomeMeasurementSpread":"10.6949" } ] } } ] } },{ "OutcomeClassTitle":"W52: Mental Health Domain (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.317", "OutcomeMeasurementSpread":"11.6243" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6.926", "OutcomeMeasurementSpread":"12.6861" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.141", "OutcomeMeasurementSpread":"12.0276" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score", "OutcomeMeasureDescription":"36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 16, 28, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 16: Physical Health Score (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.719", "OutcomeMeasurementSpread":"6.6806" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6.146", "OutcomeMeasurementSpread":"8.5192" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.407", "OutcomeMeasurementSpread":"7.6087" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Mental Health Score (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.767", "OutcomeMeasurementSpread":"11.0945" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.029", "OutcomeMeasurementSpread":"11.4967" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.929", "OutcomeMeasurementSpread":"11.2548" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Physical Health Score (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3.770", "OutcomeMeasurementSpread":"7.7829" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.799", "OutcomeMeasurementSpread":"8.8893" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.259", "OutcomeMeasurementSpread":"8.2914" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Mental Health Score (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.085", "OutcomeMeasurementSpread":"11.3660" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.364", "OutcomeMeasurementSpread":"10.9089" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.266", "OutcomeMeasurementSpread":"11.1159" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Physical Health Score (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.676", "OutcomeMeasurementSpread":"5.7405" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.250", "OutcomeMeasurementSpread":"5.7614" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.935", "OutcomeMeasurementSpread":"5.7159" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Mental Health Score (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.878", "OutcomeMeasurementSpread":"10.1983" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6.826", "OutcomeMeasurementSpread":"10.5988" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.404", "OutcomeMeasurementSpread":"10.3192" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Work Limitation Questionnaire (WLQ)", "OutcomeMeasureDescription":"WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 [no loss] to 100 [complete loss of work]).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Baseline (BL), Week (W) 4, 16, 28, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"BL: Time Management scale (n=34, 37, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"44.49", "OutcomeMeasurementSpread":"37.783" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"42.36", "OutcomeMeasurementSpread":"33.716" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"43.38", "OutcomeMeasurementSpread":"35.479" } ] } } ] } },{ "OutcomeClassTitle":"BL: Physical Demands scale (n=33, 35, 68)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"66.67", "OutcomeMeasurementSpread":"33.522" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"78.40", "OutcomeMeasurementSpread":"31.122" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"72.71", "OutcomeMeasurementSpread":"32.606" } ] } } ] } },{ "OutcomeClassTitle":"BL: Mental/Interpersonal Demands Scale(n=34,38,72)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"28.61", "OutcomeMeasurementSpread":"29.012" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"31.52", "OutcomeMeasurementSpread":"30.930" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"30.15", "OutcomeMeasurementSpread":"29.865" } ] } } ] } },{ "OutcomeClassTitle":"BL: Output Demands scale (n=33, 37, 70)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"22.61", "OutcomeMeasurementSpread":"26.832" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"30.27", "OutcomeMeasurementSpread":"35.295" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26.66", "OutcomeMeasurementSpread":"31.602" } ] } } ] } },{ "OutcomeClassTitle":"BL: WLQ Index Score (n=34, 38, 72)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"9.55", "OutcomeMeasurementSpread":"6.716" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10.74", "OutcomeMeasurementSpread":"8.045" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"10.18", "OutcomeMeasurementSpread":"7.420" } ] } } ] } },{ "OutcomeClassTitle":"W4: Time Management scale (n=31, 36, 67)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"35.32", "OutcomeMeasurementSpread":"42.425" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"31.39", "OutcomeMeasurementSpread":"36.715" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"33.21", "OutcomeMeasurementSpread":"39.203" } ] } } ] } },{ "OutcomeClassTitle":"W4: Physical Demands scale (n=29, 36, 65)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"77.16", "OutcomeMeasurementSpread":"33.013" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"83.59", "OutcomeMeasurementSpread":"29.593" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"80.72", "OutcomeMeasurementSpread":"31.083" } ] } } ] } },{ "OutcomeClassTitle":"W4:Mental/Interpersonal Demands Scale(n=32,36,68)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"17.94", "OutcomeMeasurementSpread":"26.979" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"23.39", "OutcomeMeasurementSpread":"32.878" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"20.82", "OutcomeMeasurementSpread":"30.149" } ] } } ] } },{ "OutcomeClassTitle":"W4: Output Demands scale (n=30, 36, 66)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"13.50", "OutcomeMeasurementSpread":"21.978" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"20.14", "OutcomeMeasurementSpread":"33.306" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"17.12", "OutcomeMeasurementSpread":"28.704" } ] } } ] } },{ "OutcomeClassTitle":"W4: WLQ Index Score (n=32, 37, 69)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.23", "OutcomeMeasurementSpread":"5.591" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.66", "OutcomeMeasurementSpread":"7.754" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.00", "OutcomeMeasurementSpread":"6.827" } ] } } ] } },{ "OutcomeClassTitle":"W16: Time Management scale (n=31, 35, 66)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"35.07", "OutcomeMeasurementSpread":"38.894" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"33.29", "OutcomeMeasurementSpread":"39.182" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"34.12", "OutcomeMeasurementSpread":"38.756" } ] } } ] } },{ "OutcomeClassTitle":"W16: Physical Demands scale (n=30, 32, 62)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"81.60", "OutcomeMeasurementSpread":"26.982" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"86.52", "OutcomeMeasurementSpread":"25.548" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"84.14", "OutcomeMeasurementSpread":"26.153" } ] } } ] } },{ "OutcomeClassTitle":"W16:Mental/Interpersonal Demands Scale(n=31,35,66)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"13.33", "OutcomeMeasurementSpread":"21.038" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"20.28", "OutcomeMeasurementSpread":"33.419" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"17.01", "OutcomeMeasurementSpread":"28.296" } ] } } ] } },{ "OutcomeClassTitle":"W16: Output Demands scale (n=32, 33, 65)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"11.88", "OutcomeMeasurementSpread":"20.111" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"19.55", "OutcomeMeasurementSpread":"32.485" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"15.77", "OutcomeMeasurementSpread":"27.175" } ] } } ] } },{ "OutcomeClassTitle":"W16: WLQ Index Score (n=32, 35, 67)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.88", "OutcomeMeasurementSpread":"4.715" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"8.35", "OutcomeMeasurementSpread":"7.425" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.65", "OutcomeMeasurementSpread":"6.276" } ] } } ] } },{ "OutcomeClassTitle":"W28: Time Management scale (n=34, 34, 68)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"38.68", "OutcomeMeasurementSpread":"40.100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"29.78", "OutcomeMeasurementSpread":"39.092" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"34.23", "OutcomeMeasurementSpread":"39.557" } ] } } ] } },{ "OutcomeClassTitle":"W28: Physical Demands scale (n=32, 34, 66)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"76.02", "OutcomeMeasurementSpread":"31.041" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"85.42", "OutcomeMeasurementSpread":"24.730" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"80.86", "OutcomeMeasurementSpread":"28.151" } ] } } ] } },{ "OutcomeClassTitle":"W28:Mental/Interpersonal Demands Scale(n=33,35,68)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"16.84", "OutcomeMeasurementSpread":"28.242" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"16.39", "OutcomeMeasurementSpread":"27.736" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"16.61", "OutcomeMeasurementSpread":"27.774" } ] } } ] } },{ "OutcomeClassTitle":"W28: Output Demands scale (n=33, 34, 67)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"13.94", "OutcomeMeasurementSpread":"27.408" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"14.71", "OutcomeMeasurementSpread":"28.761" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"14.33", "OutcomeMeasurementSpread":"27.892" } ] } } ] } },{ "OutcomeClassTitle":"W28: WLQ Index Score (n=34, 36, 70)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.43", "OutcomeMeasurementSpread":"6.493" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.26", "OutcomeMeasurementSpread":"6.829" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.34", "OutcomeMeasurementSpread":"6.620" } ] } } ] } },{ "OutcomeClassTitle":"W52: Time Management scale (n=31, 31, 62)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.32", "OutcomeMeasurementSpread":"43.683" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"31.88", "OutcomeMeasurementSpread":"40.686" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"41.10", "OutcomeMeasurementSpread":"42.883" } ] } } ] } },{ "OutcomeClassTitle":"W52: Physical Demands scale (n=29, 29, 58)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"78.16", "OutcomeMeasurementSpread":"30.205" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"89.74", "OutcomeMeasurementSpread":"24.410" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.95", "OutcomeMeasurementSpread":"27.838" } ] } } ] } },{ "OutcomeClassTitle":"W52:Mental/Interpersonal Demands Scale(n=30,30,60)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"25.56", "OutcomeMeasurementSpread":"36.007" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"16.89", "OutcomeMeasurementSpread":"27.293" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"21.22", "OutcomeMeasurementSpread":"31.977" } ] } } ] } },{ "OutcomeClassTitle":"W52: Output Demands scale (n=30, 29, 59)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"22.63", "OutcomeMeasurementSpread":"33.750" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"12.24", "OutcomeMeasurementSpread":"24.589" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"17.52", "OutcomeMeasurementSpread":"29.813" } ] } } ] } },{ "OutcomeClassTitle":"W52: WLQ Index Score (n=32, 31, 63)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"9.44", "OutcomeMeasurementSpread":"8.127" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.34", "OutcomeMeasurementSpread":"6.429" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.41", "OutcomeMeasurementSpread":"7.358" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category", "OutcomeMeasureDescription":"The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe).", "OutcomeMeasurePopulationDescription":"Moderate to Severe Plaque Psoriasis Population: Participants who met the inclusion criteria for the moderate to severe plaque psoriasis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"43" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"87" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Baseline: Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Baseline: Almost Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Baseline: Mild", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.1" } ] } } ] } },{ "OutcomeClassTitle":"Baseline: Moderate", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"41.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"43.2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"42.5" } ] } } ] } },{ "OutcomeClassTitle":"Baseline: Severe", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"58.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"54.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"56.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Almost Clear", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Mild", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"29.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"16.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Moderate", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"60.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"36.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"48.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 2: Severe", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"34.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"34.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"34.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Clear (n=43, 43, 86)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Almost Clear (n=43, 43, 86)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"9.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Mild (n=43, 43, 86)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"18.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"25.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"22.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Moderate (n=43, 43, 86)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"53.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"48.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"51.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 4: Severe (n=43, 43, 86)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"23.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"14.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"18.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Almost Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"14.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"17.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"15.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Mild (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"32.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"34.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"33.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Moderate (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"39.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"34.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"36.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 8: Severe (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"9.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Almost Clear (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"20.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"26.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"23.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Mild (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"34.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"41.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"38.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Moderate (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"34.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"17.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 12: Severe (n=43, 41, 84)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Clear (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"7.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Almost Clear (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"32.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"22.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"27.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Mild (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"23.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"35.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"28.9" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Moderate (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"32.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"22.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"27.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 16: Severe (n=43, 40, 83)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"12.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"9.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Almost Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"37.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"23.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"30.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Mild (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"25.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"33.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"29.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Moderate (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"23.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"25.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"24.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 20: Severe (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"11.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8.5" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Almost Clear (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"37.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"35.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"36.6" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Mild (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"23.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"20.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"22.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Moderate (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"20.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"33.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 28: Severe (n=43, 39, 82)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Clear (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"18.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"12.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Almost Clear (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"46.3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"31.6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"39.2" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Mild (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"19.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"18.4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"19.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Moderate (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"22.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"26.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"24.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 40: Severe (n=41, 38, 79)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.9" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5.1" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Clear (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"20.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"18.8" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"19.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Almost Clear (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"20.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"31.3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"25.4" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Mild (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"28.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"25.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26.8" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Moderate (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"15.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"21.9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"18.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 52: Severe (n=39, 32, 71)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"15.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"9.9" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Joint Pain Assessment (JPA)", "OutcomeMeasureDescription":"The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to \"select the number that best describes any joint pain that participant may have experienced over the past 24 hours\" with response options ranging from \"0-no joint pain\" to \"10-worst possible joint pain.\"", "OutcomeMeasurePopulationDescription":"The subjects with a medical history of ongoing psoriatic arthritis (that was defined as the MedDRA preferred term for psoriatic arthropathy regardless of meeting the inclusion criteria for the psoriatic arthritis) in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Baseline, Week 4, 16, 28, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"15" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"23" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Baseline", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.25", "OutcomeMeasurementSpread":"3.327" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.60", "OutcomeMeasurementSpread":"2.558" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"4.83", "OutcomeMeasurementSpread":"2.790" } ] } } ] } },{ "OutcomeClassTitle":"Week 4 (n=8, 14, 22)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.00", "OutcomeMeasurementSpread":"2.726" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.36", "OutcomeMeasurementSpread":"1.008" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"2.32", "OutcomeMeasurementSpread":"2.191" } ] } } ] } },{ "OutcomeClassTitle":"Week 16 (n=8, 15, 23)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.88", "OutcomeMeasurementSpread":"2.295" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.60", "OutcomeMeasurementSpread":"0.737" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.04", "OutcomeMeasurementSpread":"1.551" } ] } } ] } },{ "OutcomeClassTitle":"Week 28 (n=8, 14, 22)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1.75", "OutcomeMeasurementSpread":"1.753" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.86", "OutcomeMeasurementSpread":"0.949" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1.18", "OutcomeMeasurementSpread":"1.332" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=4, 13, 17)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.50", "OutcomeMeasurementSpread":"0.577" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.54", "OutcomeMeasurementSpread":"0.660" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.53", "OutcomeMeasurementSpread":"0.624" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response", "OutcomeMeasureDescription":"ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"62.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"41.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"66.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"100" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.3" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response", "OutcomeMeasureDescription":"ACR50 response: greater than or equal to (>=) 50 percent (%) improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"25.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"16.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"25.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"41.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"62.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"58.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"75.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"91.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"100" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"83.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"87.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"75.0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response", "OutcomeMeasureDescription":"ACR70 response: greater than or equal to (>=) 70 percent (%) improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs. Missing data was imputed as non-responder.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Percentage of participants", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"37.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"25.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"25.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"62.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"50.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"62.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"58.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"62.5" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"58.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"75.0" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"58.3" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"66.7" } ] } } ] } },{ "OutcomeClassTitle":"Week 52", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"50.0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"75.0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"66.7" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count", "OutcomeMeasureDescription":"Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Tender/painful joints", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"1.50" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-3.5", "OutcomeMeasurementSpread":"2.78" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-2.9", "OutcomeMeasurementSpread":"2.50" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-6.3", "OutcomeMeasurementSpread":"6.70" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-9.3", "OutcomeMeasurementSpread":"11.37" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-8.3", "OutcomeMeasurementSpread":"9.84" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-11.5", "OutcomeMeasurementSpread":"10.08" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-11.6", "OutcomeMeasurementSpread":"10.24" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-11.6", "OutcomeMeasurementSpread":"9.72" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-13.8", "OutcomeMeasurementSpread":"10.78" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-12.5", "OutcomeMeasurementSpread":"11.95" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-12.9", "OutcomeMeasurementSpread":"11.09" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-13.0", "OutcomeMeasurementSpread":"9.59" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-13.0", "OutcomeMeasurementSpread":"12.17" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-13.0", "OutcomeMeasurementSpread":"10.92" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-14.3", "OutcomeMeasurementSpread":"9.11" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-12.4", "OutcomeMeasurementSpread":"12.87" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-13.0", "OutcomeMeasurementSpread":"11.35" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-14.0", "OutcomeMeasurementSpread":"9.38" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-12.4", "OutcomeMeasurementSpread":"12.52" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-12.9", "OutcomeMeasurementSpread":"11.16" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-14.3", "OutcomeMeasurementSpread":"10.14" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-13.4", "OutcomeMeasurementSpread":"12.09" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-13.7", "OutcomeMeasurementSpread":"11.02" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-11.3", "OutcomeMeasurementSpread":"9.24" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-13.5", "OutcomeMeasurementSpread":"12.08" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-12.9", "OutcomeMeasurementSpread":"10.97" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count", "OutcomeMeasureDescription":"Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Swollen joints", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.8", "OutcomeMeasurementSpread":"2.22" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-3.8", "OutcomeMeasurementSpread":"5.55" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-3.1", "OutcomeMeasurementSpread":"4.68" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-5.0", "OutcomeMeasurementSpread":"4.69" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-5.3", "OutcomeMeasurementSpread":"5.80" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-5.2", "OutcomeMeasurementSpread":"5.24" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-6.0", "OutcomeMeasurementSpread":"7.35" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-6.4", "OutcomeMeasurementSpread":"4.37" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-6.3", "OutcomeMeasurementSpread":"5.19" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-6.5", "OutcomeMeasurementSpread":"6.35" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-7.0", "OutcomeMeasurementSpread":"4.44" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-6.8", "OutcomeMeasurementSpread":"4.86" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-7.3", "OutcomeMeasurementSpread":"7.85" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-7.8", "OutcomeMeasurementSpread":"3.85" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-7.6", "OutcomeMeasurementSpread":"5.12" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-7.0", "OutcomeMeasurementSpread":"8.00" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-8.9", "OutcomeMeasurementSpread":"4.42" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-8.3", "OutcomeMeasurementSpread":"5.55" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-7.3", "OutcomeMeasurementSpread":"7.85" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-7.6", "OutcomeMeasurementSpread":"4.03" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-7.5", "OutcomeMeasurementSpread":"5.21" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-7.3", "OutcomeMeasurementSpread":"7.85" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-8.8", "OutcomeMeasurementSpread":"4.20" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-8.3", "OutcomeMeasurementSpread":"5.34" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-3.0", "OutcomeMeasurementSpread":"0.00" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-8.8", "OutcomeMeasurementSpread":"4.13" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-7.2", "OutcomeMeasurementSpread":"4.38" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain", "OutcomeMeasureDescription":"Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-13.3", "OutcomeMeasurementSpread":"8.30" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-29.5", "OutcomeMeasurementSpread":"23.40" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-24.1", "OutcomeMeasurementSpread":"20.77" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-13.0", "OutcomeMeasurementSpread":"23.41" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-41.4", "OutcomeMeasurementSpread":"25.29" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-31.9", "OutcomeMeasurementSpread":"27.42" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-16.0", "OutcomeMeasurementSpread":"19.78" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-43.6", "OutcomeMeasurementSpread":"22.68" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-34.4", "OutcomeMeasurementSpread":"24.88" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-34.5", "OutcomeMeasurementSpread":"19.71" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-46.0", "OutcomeMeasurementSpread":"23.42" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-42.2", "OutcomeMeasurementSpread":"22.07" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-27.3", "OutcomeMeasurementSpread":"15.22" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-46.0", "OutcomeMeasurementSpread":"22.44" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-39.8", "OutcomeMeasurementSpread":"21.65" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-44.0", "OutcomeMeasurementSpread":"22.82" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-45.3", "OutcomeMeasurementSpread":"21.53" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-44.8", "OutcomeMeasurementSpread":"20.91" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-45.8", "OutcomeMeasurementSpread":"23.26" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-45.8", "OutcomeMeasurementSpread":"20.46" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-45.8", "OutcomeMeasurementSpread":"20.34" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-20.0", "OutcomeMeasurementSpread":"54.86" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-46.9", "OutcomeMeasurementSpread":"22.66" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-37.9", "OutcomeMeasurementSpread":"36.37" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-33.0", "OutcomeMeasurementSpread":"31.19" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-48.4", "OutcomeMeasurementSpread":"22.14" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-44.2", "OutcomeMeasurementSpread":"24.28" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis", "OutcomeMeasureDescription":"Subjects answered the following question, \"Considering the possible effects of the arthritis, how are you feeling today?\" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-8.0", "OutcomeMeasurementSpread":"8.87" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-32.6", "OutcomeMeasurementSpread":"27.55" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-24.4", "OutcomeMeasurementSpread":"25.53" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-20.5", "OutcomeMeasurementSpread":"11.27" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-43.4", "OutcomeMeasurementSpread":"27.47" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-35.8", "OutcomeMeasurementSpread":"25.33" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-23.3", "OutcomeMeasurementSpread":"19.69" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-51.3", "OutcomeMeasurementSpread":"20.53" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-41.9", "OutcomeMeasurementSpread":"23.75" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-45.0", "OutcomeMeasurementSpread":"8.83" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-52.1", "OutcomeMeasurementSpread":"21.35" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-49.8", "OutcomeMeasurementSpread":"17.99" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-40.0", "OutcomeMeasurementSpread":"13.64" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-53.0", "OutcomeMeasurementSpread":"20.96" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-48.7", "OutcomeMeasurementSpread":"19.27" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-49.5", "OutcomeMeasurementSpread":"20.09" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-49.6", "OutcomeMeasurementSpread":"20.26" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-49.6", "OutcomeMeasurementSpread":"19.27" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-52.3", "OutcomeMeasurementSpread":"11.18" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-46.3", "OutcomeMeasurementSpread":"26.67" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-48.3", "OutcomeMeasurementSpread":"22.26" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-20.8", "OutcomeMeasurementSpread":"30.24" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-50.8", "OutcomeMeasurementSpread":"20.78" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-40.8", "OutcomeMeasurementSpread":"27.24" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-40.7", "OutcomeMeasurementSpread":"16.80" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-55.3", "OutcomeMeasurementSpread":"20.51" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-51.3", "OutcomeMeasurementSpread":"19.94" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis", "OutcomeMeasureDescription":"The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-15.3", "OutcomeMeasurementSpread":"18.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-28.5", "OutcomeMeasurementSpread":"18.60" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-24.1", "OutcomeMeasurementSpread":"18.74" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-32.5", "OutcomeMeasurementSpread":"22.28" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-34.6", "OutcomeMeasurementSpread":"19.39" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-33.9", "OutcomeMeasurementSpread":"19.38" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-29.5", "OutcomeMeasurementSpread":"30.01" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-41.8", "OutcomeMeasurementSpread":"21.87" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-37.7", "OutcomeMeasurementSpread":"24.21" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-39.8", "OutcomeMeasurementSpread":"21.00" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-45.8", "OutcomeMeasurementSpread":"22.76" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-43.8", "OutcomeMeasurementSpread":"21.42" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-49.8", "OutcomeMeasurementSpread":"23.34" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-47.9", "OutcomeMeasurementSpread":"20.09" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-48.5", "OutcomeMeasurementSpread":"20.16" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-50.8", "OutcomeMeasurementSpread":"25.29" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-45.3", "OutcomeMeasurementSpread":"26.81" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-47.1", "OutcomeMeasurementSpread":"25.28" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-49.5", "OutcomeMeasurementSpread":"25.96" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-42.8", "OutcomeMeasurementSpread":"22.79" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-45.0", "OutcomeMeasurementSpread":"22.92" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-38.5", "OutcomeMeasurementSpread":"39.03" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-49.5", "OutcomeMeasurementSpread":"18.54" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-45.8", "OutcomeMeasurementSpread":"25.76" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-29.0", "OutcomeMeasurementSpread":"20.30" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-46.8", "OutcomeMeasurementSpread":"25.08" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-41.9", "OutcomeMeasurementSpread":"24.32" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)", "OutcomeMeasureDescription":"The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"mg/dL", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.20", "OutcomeMeasurementSpread":"2.137" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.68", "OutcomeMeasurementSpread":"2.231" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.52", "OutcomeMeasurementSpread":"2.114" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.20", "OutcomeMeasurementSpread":"2.267" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.69", "OutcomeMeasurementSpread":"2.272" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.53", "OutcomeMeasurementSpread":"2.178" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.28", "OutcomeMeasurementSpread":"2.354" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.70", "OutcomeMeasurementSpread":"2.222" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.56", "OutcomeMeasurementSpread":"2.167" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.28", "OutcomeMeasurementSpread":"2.351" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.68", "OutcomeMeasurementSpread":"2.235" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.54", "OutcomeMeasurementSpread":"2.174" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.30", "OutcomeMeasurementSpread":"2.337" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.69", "OutcomeMeasurementSpread":"2.189" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.56", "OutcomeMeasurementSpread":"2.139" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.33", "OutcomeMeasurementSpread":"2.387" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.59", "OutcomeMeasurementSpread":"2.336" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.50", "OutcomeMeasurementSpread":"2.246" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.30", "OutcomeMeasurementSpread":"2.337" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.15", "OutcomeMeasurementSpread":"2.770" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.20", "OutcomeMeasurementSpread":"2.526" } ] } } ] } },{ "OutcomeClassTitle":"Week 40 (n=4, 7, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-1.15", "OutcomeMeasurementSpread":"2.037" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.84", "OutcomeMeasurementSpread":"2.461" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.59", "OutcomeMeasurementSpread":"2.236" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.03", "OutcomeMeasurementSpread":"0.058" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-1.65", "OutcomeMeasurementSpread":"2.295" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-1.21", "OutcomeMeasurementSpread":"2.064" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)", "OutcomeMeasureDescription":"HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.", "OutcomeMeasurePopulationDescription":"Psoriatic Arthritis Population: Participants who met the inclusion criteria for the psoriatic arthritis in the Full Analysis Set (FAS). FAS included all participants randomized and treated with at least 1 dose of study drugs.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Week 2, 4, 8, 12, 16, 20, 28, 40, 52", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"CP-690,550 5 mg BID", "OutcomeGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"CP-690,550 10 mg BID", "OutcomeGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52." },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Total", "OutcomeGroupDescription":"(=sum across Arm/Groups)" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"4" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"8" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"12" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.19", "OutcomeMeasurementSpread":"0.239" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.28", "OutcomeMeasurementSpread":"0.376" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.25", "OutcomeMeasurementSpread":"0.329" } ] } } ] } },{ "OutcomeClassTitle":"Week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.28", "OutcomeMeasurementSpread":"0.329" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.36", "OutcomeMeasurementSpread":"0.381" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.33", "OutcomeMeasurementSpread":"0.351" } ] } } ] } },{ "OutcomeClassTitle":"Week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.28", "OutcomeMeasurementSpread":"0.359" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.38", "OutcomeMeasurementSpread":"0.399" } ] } } ] } },{ "OutcomeClassTitle":"Week 12", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.28", "OutcomeMeasurementSpread":"0.359" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.38", "OutcomeMeasurementSpread":"0.399" } ] } } ] } },{ "OutcomeClassTitle":"Week 16", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.31", "OutcomeMeasurementSpread":"0.375" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.39", "OutcomeMeasurementSpread":"0.400" } ] } } ] } },{ "OutcomeClassTitle":"Week 20", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.28", "OutcomeMeasurementSpread":"0.359" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.38", "OutcomeMeasurementSpread":"0.399" } ] } } ] } },{ "OutcomeClassTitle":"Week 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.34", "OutcomeMeasurementSpread":"0.400" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.40", "OutcomeMeasurementSpread":"0.405" } ] } } ] } },{ "OutcomeClassTitle":"Week 40", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.09", "OutcomeMeasurementSpread":"0.640" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.31", "OutcomeMeasurementSpread":"0.507" } ] } } ] } },{ "OutcomeClassTitle":"Week 52 (n=3, 8, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"-0.13", "OutcomeMeasurementSpread":"0.573" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"-0.42", "OutcomeMeasurementSpread":"0.433" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"-0.34", "OutcomeMeasurementSpread":"0.465" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"0", "EventsDescription":"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"CP-690,550 5 mg BID", "EventGroupDescription":"CP-690,550 5 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.", "EventGroupSeriousNumAffected":"3", "EventGroupSeriousNumAtRisk":"47", "EventGroupOtherNumAffected":"37", "EventGroupOtherNumAtRisk":"47" },{ "EventGroupId":"EG001", "EventGroupTitle":"CP-690,550 10 mg BID", "EventGroupDescription":"CP-690,550 10 mg tablet orally twice daily (BID) up to Week 16: CP-690,550 10 mg BID from Week 16 to 20: variable 5 or 10 mg BID from Week 20 to Week 52.", "EventGroupSeriousNumAffected":"3", "EventGroupSeriousNumAtRisk":"47", "EventGroupOtherNumAffected":"40", "EventGroupOtherNumAtRisk":"47" },{ "EventGroupId":"EG002", "EventGroupTitle":"Total", "EventGroupDescription":"(=sum across Arm/Groups)", "EventGroupSeriousNumAffected":"6", "EventGroupSeriousNumAtRisk":"94", "EventGroupOtherNumAffected":"77", "EventGroupOtherNumAtRisk":"94" } ] }, "SeriousEventList":{ "SeriousEvent":[ { "SeriousEventTerm":"Vertigo", "SeriousEventOrganSystem":"Ear and labyrinth disorders", "SeriousEventSourceVocabulary":"MedDRA 16.1", "SeriousEventAssessmentType":"Non-systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"0", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG001", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG002", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"94" } ] } },{ "SeriousEventTerm":"Herpes zoster", "SeriousEventOrganSystem":"Infections and infestations", "SeriousEventSourceVocabulary":"MedDRA 16.1", "SeriousEventAssessmentType":"Non-systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"3", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG001", "SeriousEventStatsNumAffected":"0", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG002", "SeriousEventStatsNumAffected":"3", "SeriousEventStatsNumAtRisk":"94" } ] } },{ "SeriousEventTerm":"Impetigo", "SeriousEventOrganSystem":"Infections and infestations", "SeriousEventSourceVocabulary":"MedDRA 16.1", "SeriousEventAssessmentType":"Non-systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"0", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG001", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG002", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"94" } ] } },{ "SeriousEventTerm":"Erythrodermic psoriasis", "SeriousEventOrganSystem":"Skin and subcutaneous tissue disorders", "SeriousEventSourceVocabulary":"MedDRA 16.1", "SeriousEventAssessmentType":"Non-systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"0", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG001", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG002", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"94" } ] } },{ "SeriousEventTerm":"Psoriasis", "SeriousEventOrganSystem":"Skin and subcutaneous tissue disorders", "SeriousEventSourceVocabulary":"MedDRA 16.1", "SeriousEventAssessmentType":"Non-systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"0", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG001", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"47" },{ "SeriousEventStatsGroupId":"EG002", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"94" } ] } } ] }, "OtherEventList":{ "OtherEvent":[ { "OtherEventTerm":"Anaemia", "OtherEventOrganSystem":"Blood and lymphatic system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Lymphadenitis", "OtherEventOrganSystem":"Blood and lymphatic system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Lymphadenopathy", "OtherEventOrganSystem":"Blood and lymphatic system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Vertigo", "OtherEventOrganSystem":"Ear and labyrinth disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Asthenopia", "OtherEventOrganSystem":"Eye disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Cataract", "OtherEventOrganSystem":"Eye disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Conjunctival deposit", "OtherEventOrganSystem":"Eye disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Eyelid oedema", "OtherEventOrganSystem":"Eye disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Presbyopia", "OtherEventOrganSystem":"Eye disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Abdominal discomfort", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Abdominal pain upper", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Colitis", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Constipation", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Dental caries", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Diarrhoea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Gastrooesophageal reflux disease", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Lip erosion", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Nausea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Toothache", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Fatigue", "OtherEventOrganSystem":"General disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Malaise", "OtherEventOrganSystem":"General disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Oedema", "OtherEventOrganSystem":"General disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Oedema peripheral", "OtherEventOrganSystem":"General disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Pyrexia", "OtherEventOrganSystem":"General disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hepatic function abnormal", "OtherEventOrganSystem":"Hepatobiliary disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Bronchitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Enteritis infectious", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Folliculitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Furuncle", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Gastroenteritis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Gastroenteritis norovirus", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Gastroenteritis viral", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Herpes zoster", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"10", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"13", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hordeolum", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Influenza", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"6", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Nasopharyngitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"14", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"14", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"28", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Oral herpes", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Otitis media acute", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Periodontitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Pertussis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Pharyngitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Pneumonia", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Rhinitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Salpingitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Sinusitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Subcutaneous abscess", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Tinea infection", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Tinea pedis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"6", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"10", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Tinea versicolour", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Upper respiratory tract infection", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Vaginitis gardnerella", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Arthropod bite", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Arthropod sting", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Epicondylitis", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Excoriation", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Fall", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hand fracture", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Muscle strain", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Rib fracture", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Thermal burn", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Traumatic haematoma", "OtherEventOrganSystem":"Injury, poisoning and procedural complications", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Alanine aminotransferase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Aspartate aminotransferase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Blood bilirubin increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Blood cholesterol increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Blood creatine phosphokinase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Blood triglycerides increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Gamma-glutamyltransferase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Haemoglobin decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Liver function test abnormal", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Low density lipoprotein increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Occult blood positive", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Platelet count decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Weight decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Weight increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"White blood cell count decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Diabetes mellitus", "OtherEventOrganSystem":"Metabolism and nutrition disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Dyslipidaemia", "OtherEventOrganSystem":"Metabolism and nutrition disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hypercholesterolaemia", "OtherEventOrganSystem":"Metabolism and nutrition disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hyperlipidaemia", "OtherEventOrganSystem":"Metabolism and nutrition disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Arthralgia", "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Back pain", "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Joint swelling", "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Musculoskeletal pain", "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Myalgia", "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Anogenital warts", "OtherEventOrganSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Seborrhoeic keratosis", "OtherEventOrganSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Skin papilloma", "OtherEventOrganSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Uterine leiomyoma", "OtherEventOrganSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Cervicobrachial syndrome", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Headache", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hypoaesthesia", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Neuropathy peripheral", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Post herpetic neuralgia", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Calculus ureteric", "OtherEventOrganSystem":"Renal and urinary disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Nephrolithiasis", "OtherEventOrganSystem":"Renal and urinary disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Pollakiuria", "OtherEventOrganSystem":"Renal and urinary disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Atrophic vulvovaginitis", "OtherEventOrganSystem":"Reproductive system and breast disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Cervical polyp", "OtherEventOrganSystem":"Reproductive system and breast disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Endometriosis", "OtherEventOrganSystem":"Reproductive system and breast disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Prostatitis", "OtherEventOrganSystem":"Reproductive system and breast disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Oropharyngeal pain", "OtherEventOrganSystem":"Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Upper respiratory tract inflammation", "OtherEventOrganSystem":"Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Acne", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Alopecia", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Dermatitis contact", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Dyshidrotic eczema", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Eczema", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hirsutism", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Psoriasis", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"6", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"10", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Purpura", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Seborrhoeic dermatitis", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Solar dermatitis", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Urticaria", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"94" } ] } },{ "OtherEventTerm":"Hypertension", "OtherEventOrganSystem":"Vascular disorders", "OtherEventSourceVocabulary":"MedDRA 16.1", "OtherEventAssessmentType":"Non-systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"47" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"94" } ] } } ] } }, "MoreInfoModule":{ "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictionType":"OTHER", "AgreementRestrictiveAgreement":"Yes", "AgreementOtherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results." }, "PointOfContact":{ "PointOfContactTitle":"Pfizer ClinicalTrials.gov Call Center", "PointOfContactOrganization":"Pfizer, Inc.", "PointOfContactEMail":"ClinicalTrials.gov_Inquiries@pfizer.com", "PointOfContactPhone":"1-800-718-1021" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"C000479163", "InterventionMeshTerm":"Tofacitinib" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000047428", "InterventionAncestorTerm":"Protein Kinase Inhibitors" },{ "InterventionAncestorId":"D000004791", "InterventionAncestorTerm":"Enzyme Inhibitors" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M230680", "InterventionBrowseLeafName":"Tofacitinib", "InterventionBrowseLeafAsFound":"CP-690,550", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M24407", "InterventionBrowseLeafName":"Protein Kinase Inhibitors", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000001168", "ConditionMeshTerm":"Arthritis" },{ "ConditionMeshId":"D000015535", "ConditionMeshTerm":"Arthritis, Psoriatic" },{ "ConditionMeshId":"D000011565", "ConditionMeshTerm":"Psoriasis" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000007592", "ConditionAncestorTerm":"Joint Diseases" },{ "ConditionAncestorId":"D000009140", "ConditionAncestorTerm":"Musculoskeletal Diseases" },{ "ConditionAncestorId":"D000017444", "ConditionAncestorTerm":"Skin Diseases, Papulosquamous" },{ "ConditionAncestorId":"D000012871", "ConditionAncestorTerm":"Skin Diseases" },{ "ConditionAncestorId":"D000025242", "ConditionAncestorTerm":"Spondylarthropathies" },{ "ConditionAncestorId":"D000025241", "ConditionAncestorTerm":"Spondylarthritis" },{ "ConditionAncestorId":"D000013166", "ConditionAncestorTerm":"Spondylitis" },{ "ConditionAncestorId":"D000013122", "ConditionAncestorTerm":"Spinal Diseases" },{ "ConditionAncestorId":"D000001847", "ConditionAncestorTerm":"Bone Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M3057", "ConditionBrowseLeafName":"Arthritis", "ConditionBrowseLeafAsFound":"Arthritis", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M16761", "ConditionBrowseLeafName":"Arthritis, Psoriatic", "ConditionBrowseLeafAsFound":"Psoriatic Arthritis", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M13005", "ConditionBrowseLeafName":"Psoriasis", "ConditionBrowseLeafAsFound":"Psoriasis", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M9204", "ConditionBrowseLeafName":"Joint Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10680", "ConditionBrowseLeafName":"Musculoskeletal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14257", "ConditionBrowseLeafName":"Skin Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M18296", "ConditionBrowseLeafName":"Skin Diseases, Papulosquamous", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M21620", "ConditionBrowseLeafName":"Spondylarthropathies", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M21619", "ConditionBrowseLeafName":"Spondylarthritis", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14544", "ConditionBrowseLeafName":"Spondylitis", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14502", "ConditionBrowseLeafName":"Spinal Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M3708", "ConditionBrowseLeafName":"Bone Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"T5437", "ConditionBrowseLeafName":"Spondylarthropathy", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC05", "ConditionBrowseBranchName":"Muscle, Bone, and Cartilage Diseases" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC17", "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases" },{ "ConditionBrowseBranchAbbrev":"BC01", "ConditionBrowseBranchName":"Bacterial and Fungal Diseases" },{ "ConditionBrowseBranchAbbrev":"Rare", "ConditionBrowseBranchName":"Rare Diseases" } ] } } } } } }